Komori
PRISM BioLab (206A) · RiskFirst stated

Litigation Risk Relating to Clinical Trials and Infringement of Third-Party Rights

First written in FY2025. . Latest entry: FY2025.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Litigation risk related to clinical trials and infringement of third-party intellectual property rightsA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2025First statedAnnual report

    「Although we are not currently involved in any litigation, legal disputes could arise, including lawsuits seeking damages, if compensation becomes payable in relation to any of the subjects enrolled in our clinical trials, or if we infringe a third party's rights or interests in the future, or if the other party believes that we have infringed them even when we have not.」

    Although it stated that there is currently no litigation, future legal disputes relating to clinical trials and third-party rights were listed separately as a risk for the first time.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for PRISM BioLab yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Litigation Risk Relating to Clinical Trials and Infringement of Third-Party Rights | PRISM BioLab Co.,LTD (206A) | Komori